Merck enlists Astex to search for p53 cancer drug in expanded deal
Merck has expanded its oncology collaboration with Otsuka subsidiary Astex Pharmaceuticals to the tune of a $35 million upfront payment and potential milestone payments of $500 million per program.
Astex will use its fragment-based drug discovery platform to find small molecules to target the p53 tumor suppressor protein before handing off the potential candidates to Merck for the funding and research, development and potential commercialization of the molecules.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.